Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor

Thrombosis and Haemostasis

Volumn 92, Issue 3, 2004, Pages 627-633

  Mousa, Shaker A ^a,b   Mohamed, S ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b NONE   (United States)

Author keywords

Endothelial cell tube formation; Low molecular weight heparin; Tinzaparin; Tissue factor pathway inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; FIBROBLAST GROWTH FACTOR 2; LOW MOLECULAR WEIGHT HEPARIN; TICK ANTICOAGULANT PEPTIDE; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; UMBILICAL VEIN;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FACTOR VIIA; FIBROBLAST GROWTH FACTOR 2; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIPOPROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; THROMBOPLASTIN; UMBILICAL VEINS;

EID: 4544370585     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-02-0069     Document Type: Article

References (37)

1. Felmeden DC, Blann AD, Lip GY. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003; 24: 586-603.
2. Mousa SA. Antithrombotics in thrombosis and cancer. Expert Rev Cardiovascular Ther 2003; 1: 283-91.
3. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-82.
4. Simonneau G, Sors H, Charbonnie B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337: 663-69.
5. Cosgrove RH, Zacharski LR, Racine E, et al. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002; 28: 79-87.
6. von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 2000; 16: 815-24.
7. Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999; 25: 239-43.
8. Kohanna FH, Sweeney J, Hussey S, et al. Effect of perioperative low-dose heparin administration on the course of colon cancer. Surgery 1983; 93: 433-8.
9. Green D, Hull RD, Brant R, et al. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992; 339: 1476.
10. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002; 28: 45-52.
11. Mousa SA, Fareed J. Overview: from heparin to low molecular weight heparin: beyond anticoagulation. Curr Opin Investig Drugs 2001; 2: 1077-80.
12. Mousa SA, Bozarth JM, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharm Ther 2003; 43: 2-9.
13. Norrby K, Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 1996; 16: 8-15.
14. Norrby K, Ostergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis. Int J Microcirc Clin Exp 1997; 17: 314-21.
15. Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 67: 519-28.
16. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation and angiogenesis induced by FGF2 or tissue factor/VIIa by low molecular weight heparin or tissue factor pathway inhibitor (TFPI): reversal by anti-TFPI. Blood 2002; 100: 71b.
17. American Diagnostica Inc., Greenwich, CT. http://www.americandiagnostica.com/4903%20&%204904.pdf. Accessed 6/3/04.
18. Hoppensteadt DA, Jeske W, Fareed J, et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 6: S57-S64.
19. Kageshita T, Funasaka Y, Ichihashi M, et al. Differential expression of tissue factor and tissue factor pathway inhibitor in metastatic melanoma lesions. Pigment Cell Res 2002; 15: 212-16.
20. Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002; 9: 401-6.
21. Albrecht S, Magdolen V, Herzog U, et al. Soluble tissue factor interferes with angiostatin-mediated inhibition of endothelial cell proliferation by lysine-specific interaction with plasminogen kringle domains. Thromb Haemost 2002; 88: 1054-59.
22. Ohta S, Wada H, Nakazaki T, et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22: 2991-6.
23. Amirkhosravi A, Meyer T, Chang JY, et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002; 87: 928-9.
24. Amirkhosravi A, Mousa SA, Amaya M, et al. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1: 1972-6.
25. Lykke J, Nielsen HJ. The role of tissue factor in colorectal cancer. Eur J Surg Oncol 2003; 29: 417-22.
26. Rickles FR, Shoji M, Abe K. The role of hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001; 73: 145-50.
27. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest 1994; 94: 1320-7.
28. Francis JL, Amirkhosravi A. Effect of anti-hemostatic agents on experimental tumor dissemination. Semin Thromb Hemost 2002; 28: 29-38.
29. Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa: TFPI complex in cancer patients. Thromb Res 2002; 105: 33-6.
30. Konduri SD, Tasiou A, Chandrasekar N, et al. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001; 18: 127-31.
31. Ribatti D, Vacca A, Dammacco F, et al. Angiogenesis and anti-angiogenesis in hematological malignancies. J Hematother Stem Cell Res 2003; 1: 11-22.
32. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a non-haemostatic mechanism. Cancer Res 2003; 63: 2997-3000.
33. Khorana AA, Sahni A, Atland OW, et al. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 2110-15.
34. Mousa SA, Mohamed S. Anti-angiogenic efficacy and mechanism of the low molecular weight heparin (LMWH), tinzaparin and tissue factor pathway inhibitor (TFPI): potential anti-cancer benefits. Thromb Haemost 2001; (Suppl): P1982.
35. Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol 2003; 43: 727-34.
36. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 37-52.
37. Walenga JM, Jeske WP, Samama MM, et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11: 397-407.